$1.50
+0.13 (+9.49%)
Open$1.38
Previous Close$1.37
Day High$1.53
Day Low$1.38
52W High$24.11
52W Low$14.44
Volume—
Avg Volume693.7K
Market Cap32.80M
P/E Ratio55.68
EPS$0.30
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+1,364.0% upside
Current
$1.50
$1.50
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.05M | 5.52M | 6.67M |
| Net Income | -605,390 | -589,967 | -686,380 |
| Profit Margin | -10.0% | -10.7% | -10.3% |
| EBITDA | -1,010,044 | -924,468 | -1,114,371 |
| Free Cash Flow | -597,812 | -774,673 | -818,976 |
| Rev Growth | +6.5% | -1.7% | -4.1% |
| Debt/Equity | 0.26 | 0.23 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |